अApnaFunda
Menu

SUN PHARMACEUTICAL INDUSTRIES (SUNPHARMA)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.76 / 100
Profitability 81Growth 48Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.54 / 100
Price 61Earnings 49FII/DII 50

Passes these screensDebt-light & profitableConsistent compoundersNear 52-week high

Compare withDIVIS LABORATORIESTORRENT PHARMACEUTICALSLAURUS LABS

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,904.5 latest close · 0.0% over the last 90 sessions

₹1,800₹1,900₹2,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,800₹1,900₹2,000Jul 3Sep 4Nov 9

₹1,904.5 month-end · +4.0% over 12 months

₹1,600₹1,800₹2,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,600₹1,800₹2,000Nov '25May '26Nov '26

₹1,904.5 month-end · +55.4% over 3 years

₹1,250₹1,500₹1,750₹2,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,250₹1,500₹1,750₹2,000Nov '23May '25Nov '26

₹1,904.5 month-end · +349.8% since Jan '19

₹500₹1,000₹1,500₹2,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹500₹1,000₹1,500₹2,000Jan '19Dec '22Nov '26

52-week range ₹1583.70 to ₹2046.90 · 1-year volatility 19.6%

Was the rally earned?

+4%share price, 1 yearRoughly flat
  • The share price was roughly flat over 1 year (+4%).
  • The share count barely moved.
Net profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15 ptsNet profit growthP/E change: −12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−12 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +4%+4%Share priceNet profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15ProfitP/E change: −12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−12P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +4%+4%Share price
Net profit growth+15 ptsNet profit rose about 16%, which lifts the price.
P/E change-12 ptsThe P/E fell from 42.4x to 37.8x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+55%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 45 points to the rise, while the multiple moved less (P/E 34.7x to 37.8x).
  • The share count barely moved.
Net profit growth: +44 pts. Points of the price return explained by net profit growing (or shrinking).+44 ptsNet profit growthP/E change: +11 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+11 ptsP/E changeShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1 ptsShare count changeShare price: +55%+55%Share priceNet profit growth: +44 pts. Points of the price return explained by net profit growing (or shrinking).+44ProfitP/E change: +11 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+11P/EShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1SharesShare price: +55%+55%Share price
Net profit growth+44 ptsNet profit rose about 42%, which lifts the price.
P/E change+11 ptsThe P/E rose from 34.7x to 37.8x, which lifts the price.
Share count change+1 ptsShare count was little changed. More shares would count against the price.
+153%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 235 points, but investors now pay less per rupee of profit (P/E 62.3x to 37.8x), which took 82 points back.
  • The share count rose 28%.
Net profit growth: +275 pts. Points of the price return explained by net profit growing (or shrinking).+275 ptsNet profit growthP/E change: −82 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−82 ptsP/E changeShare count change: −40 pts. Points of the price return explained by the share count changing. More shares count against the price.−40 ptsShare count changeShare price: +153%+153%Share priceNet profit growth: +275 pts. Points of the price return explained by net profit growing (or shrinking).+275ProfitP/E change: −82 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−82P/EShare count change: −40 pts. Points of the price return explained by the share count changing. More shares count against the price.−40SharesShare price: +153%+153%Share price
Net profit growth+275 ptsNet profit rose about 432%, which lifts the price.
P/E change-82 ptsThe P/E fell from 62.3x to 37.8x, which lowers the price.
Share count change-40 ptsShare count rose 28%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with DIVIS LABORATORIES

How rough has the ride been?

Maximum drawdown-32.2%recovered 2020-04
1-year volatility19.6%annualised
Beta vs sector index0.713-year daily, correlation 0.55
Volume spikes0last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%−30%2020202120222023202420252026−29.4% 0%−10%−20%−30%2020202220242026−29.4%
Largest drawdowns

-32.2% (2019-04 peak to 2020-03 low, recovered 2020-04)

-19.8% (2024-09 peak to 2025-09 low, recovered 2026-07)

-17.9% (2020-08 peak to 2020-10 low, recovered 2020-12)

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

37.8xP/E todayWithin its usual range
Against its own history32nd percentile
CheapestMedian 40.5xDearest

Usual range 32.9x to 70.7x since 2019-01.

Against Health Technology37.8x vs 37.0x
This company
37.8x
Sector median
37.0x

Close to the Health Technology median.

16.7x36.7x56.7x76.8xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x36.7x56.7x76.8xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE74thflat vs a year ago
  • Op. margin87th▼ 3 pts vs a year ago
  • Revenue growth50th▼ 4 pts vs a year ago
  • EPS growth60th▲ 22 pts vs a year ago
  • Debt/equity ↓76th▼ 4 pts vs a year ago
  • Cash cycle ↓30th▲ 3 pts vs a year ago
  • P/E ↓49th▲ 14 pts vs a year ago
  • 12M momentum46th▼ 27 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~25%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 52.0x, a holder earning 12%/yr needs earnings to grow about 25.1%/yr for 10 years, then trade at 15x.

Delivered13.0%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+12.1 ptsimplied minus delivered
Rank274thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-21%6%33% Jan 2019Nov 2026 -21%6%33% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x26.6%27.7%28.8%
15x24.0%25.1%26.2%
20x20.8%21.9%22.9%

Drag a slider to test other assumptions

Implied: 25.1%/yr

Looking back

  • Jan 2020Price implied 17%/yr; EPS has since grown 20%/yr (7.0 yrs)
  • Jan 2021Price implied 20%/yr; EPS has since grown 18%/yr (6.0 yrs)
  • Jan 2022Price implied 22%/yr; EPS has since grown 38%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1904.50
P/E
37.8x
ROCE
21.0%
Market Cap
₹4.57L cr
Revenue (TTM)
₹59911 cr
P/S
7.6x
P/B
5.5x
ROE
14.5%
Operating Margin
29.0%
Debt / Equity
0.1x
Promoter Holding
54.5%
12M Momentum
4.0%

52-week range

₹1583.70₹2046.90
69% of the way from its 52-week low to its high

Price risk

1Y volatility
19.6%
Beta vs sector
1-year daily
0.66

Balance sheet & cash

Interest cover
operating profit ÷ interest
45.1x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.20x
Share count, 1Y
unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 9.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate23%Within range

Median quarterly effective tax rate over about 2.5 years: 23.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.20xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.20x (cash from operations ₹38,626 cr, net profit ₹32,084 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+6 daysWithin range

Debtor days are above the median of the previous three fiscal years by 6 days (97 vs 91). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress9% of fixed assetsWithin range

Capital work-in-progress is 9% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+38 days / 2 yrsNear threshold

Days payable changed by +38 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 2.5 pts; FIIs trimmed 2.2 pts.
  • The number of shareholders rose from 6.2 lakh to 7.1 lakh (+15%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters54.5%54.5%0.0 pts
FIIs16.8%14.5%-2.2 pts
DIIs19.6%22.1%+2.5 pts
Public and others9.1%8.8%-0.2 pts

Number of shareholders

7.1 lakhshareholders+15% since Sep '23
6.1L6.6L7.0L7.4L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 6.2 lakh
Dec '23: 6.1 lakh
Mar '24: 6.3 lakh
Jun '24: 6.7 lakh
Sep '24: 6.6 lakh
Dec '24: 6.9 lakh
Mar '25: 7.0 lakh
Jun '25: 7.2 lakh
Sep '25: 7.4 lakh
Dec '25: 7.1 lakh
Mar '26: 6.9 lakh
Jun '26: 7.1 lakh
 6.1L6.6L7.0L7.4L Sep '23Sep '24Sep '25Jun '26
Sep '23: 6.2 lakh
Dec '23: 6.1 lakh
Mar '24: 6.3 lakh
Jun '24: 6.7 lakh
Sep '24: 6.6 lakh
Dec '24: 6.9 lakh
Mar '25: 7.0 lakh
Jun '25: 7.2 lakh
Sep '25: 7.4 lakh
Dec '25: 7.1 lakh
Mar '26: 6.9 lakh
Jun '26: 7.1 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−8.6%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like SUN PHARMACEUTICAL INDUSTRIES today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −19% to +4% vs the market, against −4% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −4.6%, 80% range −10.2% to −1.7%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−40%−20%0%+20%+40%
PIIND · Jul 2025: −38.6% vs market
KANSAINER · Oct 2020: −33.7% vs market
ITC · May 2023: −33.3% vs market
UBL · Feb 2020: −31.5% vs market
DABUR · Jan 2023: −30.4% vs market
AIAENG · Aug 2020: −29.5% vs market
MANKIND · Dec 2024: −27.8% vs market
SUPREMEIND · May 2021: −25.1% vs market
SHREECEM · Nov 2020: −23.9% vs market
LTTS · Mar 2024: −20.8% vs market
MARUTI · Feb 2020: −19.7% vs market
CIPLA · Feb 2025: −18.9% vs market
DRREDDY · Jul 2023: −18.9% vs market
GODREJCP · Dec 2023: −18.6% vs market
INFY · Aug 2021: −18.4% vs market
TCS · Jun 2022: −15.8% vs market
ZYDUSLIFE · Mar 2024: −15.1% vs market
BERGEPAINT · Jun 2025: −14.1% vs market
CUMMINSIND · Apr 2024: −13.0% vs market
ASIANPAINT · Jul 2022: −11.7% vs market
ACC · Aug 2021: −11.1% vs market
ATUL · Jun 2021: −10.6% vs market
BAJAJ-AUTO · May 2024: −9.9% vs market
AMBUJACEM · Aug 2021: −8.9% vs market
TECHM · Feb 2020: −8.7% vs market
UNITDSPR · Nov 2024: −8.6% vs market
HINDUNILVR · Apr 2025: −8.2% vs market
3MINDIA · Jul 2023: −7.9% vs market
PIDILITIND · Jan 2025: −6.0% vs market
ABBOTINDIA · Feb 2023: −5.8% vs market
VOLTAS · Jan 2021: −4.2% vs market
ULTRACEMCO · Jun 2023: −4.0% vs market
ALKEM · Oct 2025: −1.9% vs market
BALKRISIND · May 2021: −1.7% vs market
BOSCHLTD · Jan 2023: −0.5% vs market
HCLTECH · Jan 2023: +1.0% vs market
SIEMENS · Jan 2023: +1.7% vs market
DMART · Aug 2024: +4.7% vs market
JBCHEPHARM · Feb 2023: +6.0% vs market
LALPATHLAB · Aug 2025: +8.6% vs market
HAL · Oct 2025: +9.6% vs market
MARICO · May 2025: +12.2% vs market
HAVELLS · Dec 2020: +13.0% vs market
DIVISLAB · Sep 2024: +13.3% vs market
NESTLEIND · Apr 2025: +14.5% vs market
WIPRO · Mar 2020: +17.1% vs market
BEL · Feb 2024: +25.2% vs market
POLYCAB · Jun 2023: +29.5% vs market
EICHERMOT · May 2025: +31.6% vs market
TORNTPHARM · Oct 2025: +36.9% vs market
Similar setups −8.6%All companies −4.0%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median
−8.6%
All companies' median
−4.0%
Beat the market
30% vs 46%

50 past situations · 50 companies · 34 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
HINDUNILVR
Consumer Non-Durables		 Apr 2025 50x27% +5%−23% −8%
DABUR
Consumer Non-Durables		 Jan 2023 57x27% +4%−8% −30%
PIDILITIND
Process Industries		 Jan 2025 76x30% +13%−15% −6%
NESTLEIND
Consumer Non-Durables		 Apr 2025 77x— −5%−13% +15%
UNITDSPR
Consumer Non-Durables		 Nov 2024 79x28% +46%−7% −9%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
WIPRO
Technology Services		 Mar 2020 13x19% −23%−34% +17%
TECHM
Technology Services		 Feb 2020 16x25% −11%−12% −9%
CIPLA
Health Technology		 Feb 2025 25x23% −5%−16% −19%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and revenue growth. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SUN PHARMACEUTICAL INDUSTRIES. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

HINDUSTAN UNILEVERHINDUNILVR
Consumer Non-Durables
72%similar
market caprevenue
EICHER MOTORSEICHERMOT
Consumer Durables
70%similar
market capP/E
MARICOMARICO
Consumer Non-Durables
70%similar
volatilityEPS growth
BHARAT ELECTRONICSBEL
Electronic Technology
69%similar
market caprevenue
UNITED SPIRITSUNITDSPR
Consumer Non-Durables
68%similar
debt/equitypromoter holding
ALKEM LABORATORIESALKEM
Health Technology
70%similar
ROCEvolatility
DIVIS LABORATORIESDIVISLAB
Health Technology
69%similar
market capROCE
AJANTA PHARMAAJANTPHARM
Health Technology
67%similar
debt/equityP/E

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Sep '19

  1. SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  2. JunResultsYear-on-year EPS growth turned positive.
  3. AprPriceVolume reached 10.0x its 50-day median on 2026-04-27; price +7.0% that day.
  4. SepResultsYear-on-year EPS growth turned negative.
  5. SepPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  6. SepPriceVolume reached 5.1x its 50-day median on 2025-09-01; price -2.0% that day.
  7. MarPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  8. JunResultsRevenue (TTM) reached a new high of ₹48,497 cr.
Show 22 earlier events
  1. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  2. MayPriceVolume reached 5.2x its 50-day median on 2024-05-23; price -2.9% that day.
  3. OctValuationP/E fell below the 10th percentile of its own history to date (30.8x).
  4. JunResultsRevenue (TTM) reached a new high of ₹43,886 cr.
  5. JunValuationP/E fell below the 10th percentile of its own history to date (29.8x).
  6. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  7. JunDividendDividend payout cut from 73% to 33% of profit.
  8. OctValuationP/E crossed above the 90th percentile of its own history to date (74.6x).
  9. JunResultsYear-on-year EPS growth turned positive.
  10. JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
  11. MayPriceVolume reached 9.9x its 50-day median on 2022-05-31; price -3.1% that day.
  12. NovPriceVolume reached 6.6x its 50-day median on 2021-11-02; price +0.4% that day.
  13. JulPriceVolume reached 9.9x its 50-day median on 2021-07-30; price +10.1% that day.
  14. JunResultsYear-on-year EPS growth turned negative.
  15. JunValuationP/E crossed above the 90th percentile of its own history to date (55.8x).
  16. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 2nd quartile).
  17. NovPriceVolume reached 5.6x its 50-day median on 2020-11-04; price +3.9% that day.
  18. JunResultsRevenue (TTM) reached a new high of ₹32,838 cr.
  19. AprPriceRegained the 2019-04 peak, 1 month after the low.
  20. MarPriceFell 32% from the Apr 2019 peak to the Mar 2020 low.
  21. MarPriceVolume reached 6.4x its 50-day median on 2020-03-04; price +3.0% that day.
  22. SepPriceVolume reached 5.8x its 50-day median on 2019-09-04; price -2.9% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1137.8x₹59911 cr14.5%21.0%0.1x
2026-1035.3x₹59911 cr14.5%21.0%0.1x
2026-0936.0x₹59911 cr14.5%21.0%0.1x
2026-0841.5x₹58462 cr13.8%21.0%0.1x
2026-0741.6x₹58462 cr13.8%21.0%0.1x
2026-0638.9x₹58462 cr13.8%21.0%0.1x
2026-0539.5x₹56809 cr15.2%20.0%0.0x
2026-0439.7x₹56809 cr15.2%20.0%0.0x
2026-0338.6x₹56809 cr15.2%20.0%0.0x
2026-0239.9x₹54963 cr14.5%20.0%0.0x
2026-0136.6x₹54963 cr14.5%20.0%0.0x
2025-1239.5x₹54963 cr14.5%20.0%0.0x
2025-1142.4x₹53776 cr14.4%20.0%0.0x
2025-1039.1x₹53776 cr14.4%20.0%0.0x
2025-0936.9x₹53776 cr14.4%20.0%0.0x
2025-0835.0x₹52578 cr15.2%20.0%0.0x
2025-0737.5x₹52578 cr15.2%20.0%0.0x
2025-0636.8x₹52578 cr15.2%20.0%0.0x
2025-0535.2x₹51602 cr18.0%17.0%0.1x
2025-0438.5x₹51602 cr18.0%17.0%0.1x
2025-0336.4x₹51602 cr18.0%17.0%0.1x
2025-0234.6x₹50308 cr17.5%17.0%0.1x
2025-0137.9x₹50308 cr17.5%17.0%0.1x
2024-1240.9x₹50308 cr17.5%17.0%0.1x
2024-1141.1x₹49209 cr16.4%17.0%0.1x
2024-1042.7x₹49209 cr16.4%17.0%0.1x
2024-0944.5x₹49209 cr16.4%17.0%0.1x
2024-0845.6x₹48497 cr15.1%17.0%0.1x
2024-0743.1x₹48497 cr15.1%17.0%0.1x
2024-0638.1x₹48497 cr15.1%17.0%0.1x
2024-0541.3x₹43886 cr15.2%16.0%0.1x
2024-0442.5x₹43886 cr15.2%16.0%0.1x
2024-0345.9x₹43886 cr15.2%16.0%0.1x
2024-0244.7x₹43886 cr15.2%16.0%0.1x
2024-0140.2x₹43886 cr15.2%16.0%0.1x
2023-1235.7x₹43886 cr15.2%16.0%0.1x
2023-1134.7x₹43886 cr15.2%16.0%0.1x
2023-1030.8x₹43886 cr15.2%16.0%0.1x
2023-0932.8x₹43886 cr15.2%16.0%0.1x
2023-0831.5x₹43886 cr15.2%16.0%0.1x
2023-0732.4x₹43886 cr15.2%16.0%0.1x
2023-0629.8x₹43886 cr15.2%16.0%0.1x
2023-0571.5x₹38654 cr7.1%17.0%0.0x
2023-0472.4x₹38654 cr7.1%17.0%0.0x
2023-0372.1x₹38654 cr7.1%17.0%0.0x
2023-0270.1x₹38654 cr7.1%17.0%0.0x
2023-0175.8x₹38654 cr7.1%17.0%0.0x
2022-1273.4x₹38654 cr7.1%17.0%0.0x
2022-1176.7x₹38654 cr7.1%17.0%0.0x
2022-1074.6x₹38654 cr7.1%17.0%0.0x
2022-0969.5x₹38654 cr7.1%17.0%0.0x
2022-0865.5x₹38654 cr7.1%17.0%0.0x
2022-0769.1x₹38654 cr7.1%17.0%0.0x
2022-0660.9x₹38654 cr7.1%17.0%0.0x
2022-0571.1x₹33498 cr4.9%13.0%0.1x
2022-0476.7x₹33498 cr4.9%13.0%0.1x
2022-0375.6x₹33498 cr4.9%13.0%0.1x
2022-0269.7x₹33498 cr4.9%13.0%0.1x
2022-0169.0x₹33498 cr4.9%13.0%0.1x
2021-1269.9x₹33498 cr4.9%13.0%0.1x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback